773 related articles for article (PubMed ID: 31540840)
21. HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: Findings from respondent-driven sampling surveys.
Handanagic S; Bozicevic I; Civljak M; Dominkovic Z; Sevic S; Barbaric J; Nemeth Blazic T; Dakovic Rode O; Begovac J
Int J Drug Policy; 2016 Jun; 32():57-63. PubMed ID: 27160504
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials.
van Santen DK; Lodi S; Dietze P; van den Boom W; Hayashi K; Dong H; Cui Z; Maher L; Hickman M; Boyd A; Prins M
Addiction; 2023 Jun; 118(6):1116-1126. PubMed ID: 36710474
[TBL] [Abstract][Full Text] [Related]
23. Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial.
Solomon SS; Quinn TC; Solomon S; McFall AM; Srikrishnan AK; Verma V; Kumar MS; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Thomas DL; Sachdeva KS; Lucas GM; Mehta SH
J Hepatol; 2020 Jan; 72(1):67-74. PubMed ID: 31604081
[TBL] [Abstract][Full Text] [Related]
24. Needle and syringe sharing among people who have recently injected drugs in Australia: The ETHOS Engage Study.
Farooq A; Valerio H; Wheeler A; Martinello M; Henderson C; Silk D; Degenhardt L; Read P; Dore GJ; Grebely J; Cunningham EB;
Drug Alcohol Rev; 2024 May; 43(4):1019-1028. PubMed ID: 38630939
[TBL] [Abstract][Full Text] [Related]
25. Risk behaviors, prevalence of HIV and hepatitis C virus infection and population size of current injection drug users in a China-Myanmar border city: results from a Respondent-Driven Sampling Survey in 2012.
Li L; Assanangkornchai S; Duo L; McNeil E; Li J
PLoS One; 2014; 9(9):e106899. PubMed ID: 25203256
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C among people who inject drugs in Tbilisi, Georgia: an urgent need for prevention and treatment.
Bouscaillou J; Champagnat J; Luhmann N; Avril E; Inaridze I; Miollany V; Labartkava K; Kirtadze I; Butsashvili M; Kamkamidze G; Pataut D
Int J Drug Policy; 2014 Sep; 25(5):871-8. PubMed ID: 24529802
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of HIV and other infections and injection behaviours among people who inject drugs in Addis Ababa, Ethiopia.
Demissie M; Johnston LG; Muleta M; Desyebelew D; Belete W; G/Egxiabehre A; Gezahegn N; Kassa D; Aseffa Y
Afr J AIDS Res; 2018 Sep; 17(3):259-264. PubMed ID: 30319040
[TBL] [Abstract][Full Text] [Related]
28. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
Allen EJ; Palmateer NE; Hutchinson SJ; Cameron S; Goldberg DJ; Taylor A
Int J Drug Policy; 2012 Sep; 23(5):346-52. PubMed ID: 22940142
[TBL] [Abstract][Full Text] [Related]
29. Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada.
Jacka B; Roy É; Høj S; Minoyan N; Artenie AA; Zang G; Jutras-Aswad D; Bruneau J
J Viral Hepat; 2019 Dec; 26(12):1413-1422. PubMed ID: 31433888
[TBL] [Abstract][Full Text] [Related]
30. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
[TBL] [Abstract][Full Text] [Related]
31. A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugs.
Hope VD; Harris RJ; Vickerman P; Platt L; Shute J; Cullen KJ; Ijaz S; Mandal S; Ncube F; Desai M; Parry JV
Euro Surveill; 2018 Nov; 23(47):. PubMed ID: 30482265
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and correlates of violence among sexual and injecting partners of people who inject drugs living with HIV in Kenya: a cross-sectional study.
Aung SWKH; Kingston H; Mbogo LW; Sambai B; Monroe-Wise A; Ludwig-Barron NT; Bukusi D; Sinkele W; Gitau E; Masyuko S; Herbeck JT; Farquhar C; Guthrie BL
Harm Reduct J; 2023 Nov; 20(1):164. PubMed ID: 37919736
[TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 antibody prevalence, correlates, and access to harm reduction services among people who inject drugs living with and without HIV and their partners in Kenya.
Doshi S; Kingston H; Tseng AS; Chohan BH; Sambai B; Guthrie BL; Monroe-Wise A; Mbogo LW; Masyuko S; Tram KH; Sinkele W; Macharia P; Bukusi D; Herbeck JT; Farquhar C
Harm Reduct J; 2023 Feb; 20(1):21. PubMed ID: 36823596
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working?
Taylor A; Goldberg D; Hutchinson S; Cameron S; Gore SM; McMenamin J; Green S; Pithie A; Fox R
J Infect; 2000 Mar; 40(2):176-83. PubMed ID: 10841096
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis C virus prevalence, determinants, and cascade of care among people who inject drugs in Iran.
Khezri M; Mirzazadeh A; Shokoohi M; Sharafi H; Ghalekhani N; Tavakoli F; Mehmandoost S; Mousavian G; Imani M; Kakavand-Ghalehnoei R; Komasi A; Gouya MM; Haghdoost AA; McFarland W; Karamouzian M; Sharifi H
Drug Alcohol Depend; 2023 Feb; 243():109751. PubMed ID: 36621200
[TBL] [Abstract][Full Text] [Related]
36. Epidemiological aspects of HCV infection in non-injecting drug users in the Brazilian state of Pará, eastern Amazon.
Oliveira-Filho AB; Sawada L; Pinto LC; Locks D; Bahia SL; Castro JA; Hermes RB; Brasil-Costa I; Amaral CE; Lemos JA
Virol J; 2014 Feb; 11():38. PubMed ID: 24564954
[TBL] [Abstract][Full Text] [Related]
37. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
[TBL] [Abstract][Full Text] [Related]
38. Baseline prevalence and correlates of HIV and HCV infection among people who inject drugs accessing a syringe services program; Miami, FL.
Bartholomew TS; Onugha J; Bullock C; Scaramutti C; Patel H; Forrest DW; Feaster DJ; Tookes HE
Harm Reduct J; 2020 Jun; 17(1):40. PubMed ID: 32522201
[TBL] [Abstract][Full Text] [Related]
39. Short and sporadic injecting cessation episodes as predictors of incident hepatitis C virus infection: findings from a cohort study of people who inject drugs in Montréal, Canada.
Fortier E; Artenie AA; Zang G; Jutras-Aswad D; Roy É; Grebely J; Bruneau J
Addiction; 2019 Aug; 114(8):1495-1503. PubMed ID: 30957310
[TBL] [Abstract][Full Text] [Related]
40. HIV and hepatitis B and C co-infection among people who inject drugs in Zanzibar.
Khatib A; Matiko E; Khalid F; Welty S; Ali A; Othman A; Haji S; Dahoma M; Rutherford G
BMC Public Health; 2017 Nov; 17(1):917. PubMed ID: 29183287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
